{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:19:03Z","timestamp":1786997943526,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.06.102","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:20:40Z","timestamp":1436314840000},"page":"4594-4601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study"],"prefix":"10.1016","volume":"33","author":[{"given":"Christoph F.R","family":"Hatz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Rohrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kramme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire-Anne","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Alaimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica Gambillara","family":"Fonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.06.102_bib0205","series-title":"Guidelines for the control of shigellosis, including epidemics due to Shigella dysentaeriae type 1","author":"WHO","year":"2005"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7883\/yoken.JJID.2001.121","article-title":"Changing patterns of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta, India","volume":"54","author":"Niyogi","year":"2001","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0215","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0220","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4269\/ajtmh.2004.70.663","article-title":"Short report. High incidence of shigellosis among Peruvian soldiers deployed in the Amazon River basin","volume":"70","author":"Jones","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0225","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1017\/S095026880600642X","article-title":"Epidemiology and genetic characterization of Shigella flexneri strains isolated from three paediatric populations in Egypt (2000\u20132004)","volume":"134","author":"Ahmed","year":"2006","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0230","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4269\/ajtmh.2004.71.367","article-title":"Epidemiology of Shigella-associated diarrhea in rural Egyptian children","volume":"71","author":"Abu-Elyazeed","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0235","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1128\/IAI.73.12.8027-8032.2005","article-title":"Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers","volume":"73","author":"Orr","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0240","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.trstmh.2006.02.007","article-title":"Molecular epidemiology of multidrug-resistant Shigella dysenteriae type 1 causing dysentery outbreaks in Central African Republic, 2003\u20132004","volume":"100","author":"Bercion","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0245","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/AAC.48.2.681-684.2004","article-title":"Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India","volume":"48","author":"Pazhani","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"Apr. (2)","key":"10.1016\/j.vaccine.2015.06.102_bib0250","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/00034983.1996.11813034","article-title":"Shigella infections","volume":"90","author":"Shears","year":"1996","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0255","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS). A prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0260","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/infdis\/162.3.711","article-title":"Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin","volume":"162","author":"Bennish","year":"1990","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2334-5-89","article-title":"The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance","volume":"5","author":"Agtini","year":"2005","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0270","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1371\/journal.pmed.0030353","article-title":"A multicentre study of Shigella diarrhoea in six Asian countries. Disease burden, clinical manifestations, and microbiology","volume":"3","author":"Seidlein","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0275","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrgastro.2013.12","article-title":"Progress and pitfalls in Shigella vaccine research","volume":"10","author":"Barry","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0280","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1128\/IAI.66.8.3862-3866.1998","article-title":"Vector development for the expression of foreign proteins in the vaccine strain Brucella abortus S19","volume":"66","author":"Comerci","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0285","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2010.10.035","article-title":"Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in MatLab, Bangladesh","volume":"29","author":"Rahman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0290","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.vaccine.2005.07.014","article-title":"Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei. Preclinical studies and a Phase I trial","volume":"24","author":"McKenzie","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0295","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/14760584.5.5.669","article-title":"Live-attenuated Shigella vaccines","volume":"5","author":"Venkatesan","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0300","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.coi.2012.03.014","article-title":"Vaccines against mucosal infections","volume":"24","author":"Holmgren","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0305","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0310","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/0264-410X(94)90153-8","article-title":"Safety and immunogenicity of the oral E. coli K12-S. Flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers","volume":"12","author":"Cohen","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0315","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1128\/IAI.64.10.4074-4077.1996","article-title":"Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers","volume":"64","author":"Cohen","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0320","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1086\/314759","article-title":"Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children","volume":"179","author":"Ashkenazi","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0325","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0330","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1\u20134-year-old Israeli children","volume":"28","author":"Passwell","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0335","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/IAI.69.3.1351-1357.2001","article-title":"Safety and immunogenicity of improved Shigella O-specific polysaccharide\u2013protein conjugate vaccines in adults in Israel","volume":"69","author":"Passwell","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0340","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2174\/138527281808140616154704","article-title":"Synthesis of glycoconjugate vaccines in genetically engineered bacterial cells","volume":"18","author":"Fernandez","year":"2014","journal-title":"COC"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0345","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1073\/pnas.0500044102","article-title":"Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli","volume":"102","author":"Feldman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0350","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jit800","article-title":"Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli","volume":"209","author":"Wacker","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0355","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/sj.emboj.7601087","article-title":"Definition of the bacterial N-glycosylation site consensus sequence","volume":"25","author":"Kowarik","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0360","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1128\/IAI.58.7.2367-2374.1990","article-title":"Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A","volume":"58","author":"Fattom","year":"1990","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0365","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/IAI.61.3.1023-1032.1993","article-title":"Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A","volume":"61","author":"Fattom","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0370","first-page":"540","article-title":"Clinical trials of Shigella vaccines. Two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nat Rev"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0375","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-3083.2002.01124.x","article-title":"Current state of pneumococcal vaccines","volume":"56","author":"Wuorimaa","year":"2002","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0380","first-page":"85","article-title":"Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease","volume":"7","author":"Hedari","year":"2014","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0385","doi-asserted-by":"crossref","first-page":"e25398","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0390","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/infdis\/161.5.821","article-title":"Polysaccharide\u2013protein conjugates: a new generation of vaccines","volume":"161","author":"Robbins","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0395","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/IAI.61.9.3678-3687.1993","article-title":"Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids","volume":"61","author":"Taylor","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.102_bib0400","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.vaccine.2004.06.052","article-title":"Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines","volume":"23","author":"Huebner","year":"2004","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T22:36:29Z","timestamp":1748471789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15009196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":40,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X15009196"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.102","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}